Skip to main content
    S

    Syndax Pharmaceuticals Inc (SNDX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $9.13
    -0.32 (-3.39%)

    Market Cap: $850.77M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Syndax Pharmaceuticals Inc (SNDX) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Syndax Pharmaceuticals are Annexon (ANNX), Structure Therapeutics Inc. American Depositary Shares (GPCR) and Janux Therapeutics (JANX). By market cap, Syndax Pharmaceuticals ranks 6th of the 13 companies on this page; Nurix Therapeutics (NRIX) is the largest at $1.69B.

    Peer Comparison

    SNDX's ROIC of -65.0% is below the peer median of -58.7%, and its revenue growth of 81.6% is above the median of -3.5%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Syndax Pharmaceuticals (SNDX)$850.77MN/A2.8x-72.3%-65.0%81.6%0.00%
    Annexon Inc (ANNX)$747.79MN/AN/A0.0%-84.6%0.0%0.00%
    Structure Therapeutics Inc. American Depositary Shares (GPCR)$1.43BN/AN/A0.0%N/A0.0%0.00%
    Janux Therapeutics Inc (JANX)$695.65MN/A29.6x0.0%N/A-7.1%0.00%
    Solid Biosciences LLC (SLDB)$763.42MN/AN/A0.0%N/A-100.0%0.00%
    Theravance Biopharma Inc (TBPH)$884.18M95.1x8.4x51.6%N/A-20.9%0.00%
    Nurix Therapeutics Inc (NRIX)$1.69B6.4x2.3x42.0%N/A8426.0%0.00%
    Shattuck Labs Inc (STTK)$473.57MN/AN/A0.0%N/A-66.6%0.00%
    Jade Biosciences, Inc. (JBIO)$1.03BN/AN/A0.0%N/A0.0%0.00%
    CytomX Therapeutics Inc (CTMX)$444.73MN/A31.0x0.0%-32.8%-71.7%0.00%
    Design Therapeutics Inc (DSGN)$670.46MN/AN/A0.0%N/A0.0%0.00%
    Immix Biopharma Inc (IMMX)$657.09MN/AN/A0.0%-14.9%0.0%0.00%
    Inventiva Sa (IVA)$879.90MN/A133.4x0.0%-327.7%-76.7%0.00%
    Peer median$755.61M50.8x29.6x0.0%-58.7%-3.5%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Syndax Pharmaceuticals, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Annexon Inc (ANNX)
    Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for autoimmune and neurodegenerative diseases.
    ANNX competitors
    Structure Therapeutics Inc. American Depositary Shares (GPCR)
    Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic...
    GPCR competitors
    Janux Therapeutics Inc (JANX)
    Janux Therapeutics, Inc., a biopharmaceutical company, develops therapies based on the patented Tumor Activated T Cell Engager (TRACTr) platform technology...
    JANX competitors
    Solid Biosciences LLC (SLDB)
    Solid Biosciences Inc., a life sciences company, is dedicated to developing therapies for Duchenne muscular dystrophy (DMD) in the United States.
    SLDB competitors
    Theravance Biopharma Inc (TBPH)
    Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and markets organ-selective drugs in the United States, Europe...
    Nurix Therapeutics Inc (NRIX)
    Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development...
    NRIX competitors
    Shattuck Labs Inc (STTK)
    Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapies for the treatment of cancer and autoimmune diseases in the United States.
    STTK competitors
    Jade Biosciences, Inc. (JBIO)
    Jade Biosciences, Inc. is a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune...
    JBIO competitors
    CytomX Therapeutics Inc (CTMX)
    CytomX Therapeutics, Inc. is an oncology-focused biopharmaceutical company in the United States.
    CTMX competitors
    Design Therapeutics Inc (DSGN)
    Design Therapeutics, Inc. develops therapies for the treatment of degenerative disorders caused by nucleotide repeat expansions.
    DSGN competitors
    Immix Biopharma Inc (IMMX)
    Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, is dedicated to the development of various tissue-specific therapies in oncology...
    IMMX competitors
    Inventiva Sa (IVA)
    Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic...

    Frequently Asked Questions About SNDX

    Who are Syndax Pharmaceuticals' main competitors?

    The companies most similar to Syndax Pharmaceuticals include Annexon (ANNX), Structure Therapeutics Inc. American Depositary Shares (GPCR), Janux Therapeutics (JANX), Solid Biosciences LLC (SLDB) and Theravance Biopharma (TBPH), listed from the closest match.

    Who is Syndax Pharmaceuticals' biggest competitor?

    Nurix Therapeutics (NRIX) is the largest of the similar companies at $1.69B; Annexon (ANNX) is the closest match by business profile, size, sector and industry.

    How does SNDX stock compare with its competitors?

    SNDX's P/S is 2.8x against a peer median of 29.6x; its net margin is -72.3% against a peer median of 0.0%.

    Which of Syndax Pharmaceuticals' competitors pays a higher dividend?

    Syndax Pharmaceuticals pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Syndax Pharmaceuticals bigger than its competitors?

    No. Syndax Pharmaceuticals is 6th by market cap among the 13 companies on this page; the largest is Nurix Therapeutics (NRIX) at $1.69B.